PTC Therapeutics announced that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA. PTC expects to submit the sepiapterin NDA to the FDA no later than the third quarter of 2024. In addition, submissions are planned in a number of additional countries in 2024 including Brazil and Japan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Biotech Alert: Searches spiking for these stocks today
- PTC Therapeutics price target raised to $26 from $18 at Citi
- RBC ‘somewhat surprised’ Sarepta shares not stronger on Translarna news
- PTC Therapeutics price target raised to $46 from $35 at Jefferies
- Rubrik and Marex Group initiated: Wall Street’s top analyst calls